array:21 [
  "pii" => "X2013251413003170"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2013.Feb.11697"
  "estado" => "S300"
  "fechaPublicacion" => "2013-05-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia (English Version). 2013;33:377-80"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 6037
    "formatos" => array:3 [
      "EPUB" => 304
      "HTML" => 5062
      "PDF" => 671
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699513003173"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2013.Feb.11697"
      "estado" => "S300"
      "fechaPublicacion" => "2013-05-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2013;33:377-80"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 14148
        "formatos" => array:3 [
          "EPUB" => 295
          "HTML" => 13233
          "PDF" => 620
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "Líquido peritoneal turbio acelular y uso de antagonistas del calcio en diálisis peritoneal"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "377"
            "paginaFinal" => "380"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Turbid acellular peritoneal fluid and the use of calcium antagonists in peritoneal dialysis"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig1"
            "etiqueta" => "Fig. 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier España"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "11697_19904_35171_es_11697_f1.jpg"
                "Alto" => 579
                "Ancho" => 900
                "Tamanyo" => 144348
              ]
            ]
            "descripcion" => array:1 [
              "es" => "Líquido peritoneal turbio acelular en paciente tratado con manidipino"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Loreley BETANCOURT CASTELLANOS, Loreley Betancourt-Castellanos, Esther Ponz Clemente, Esther Ponz-Clemente, Maria Sol Otero López, M. Sol Otero-López, Conchita Blasco Cabañas, Conchita Blasco-Cabañas, Dolors Marquina Parra, Dolors Marquina-Parra, Manuel GARCIA GARCIA, Manuel García-García"
            "autores" => array:12 [
              0 => array:2 [
                "nombre" => "Loreley"
                "apellidos" => "BETANCOURT CASTELLANOS"
              ]
              1 => array:2 [
                "nombre" => "Loreley"
                "apellidos" => "Betancourt-Castellanos"
              ]
              2 => array:2 [
                "nombre" => "Esther"
                "apellidos" => "Ponz Clemente"
              ]
              3 => array:2 [
                "nombre" => "Esther"
                "apellidos" => "Ponz-Clemente"
              ]
              4 => array:2 [
                "nombre" => "Maria Sol"
                "apellidos" => "Otero López"
              ]
              5 => array:2 [
                "nombre" => "M. Sol"
                "apellidos" => "Otero-López"
              ]
              6 => array:2 [
                "nombre" => "Conchita"
                "apellidos" => "Blasco Cabañas"
              ]
              7 => array:2 [
                "nombre" => "Conchita"
                "apellidos" => "Blasco-Cabañas"
              ]
              8 => array:2 [
                "nombre" => "Dolors"
                "apellidos" => "Marquina Parra"
              ]
              9 => array:2 [
                "nombre" => "Dolors"
                "apellidos" => "Marquina-Parra"
              ]
              10 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "GARCIA GARCIA"
              ]
              11 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "García-García"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251413003170"
          "doi" => "10.3265/Nefrologia.pre2013.Feb.11697"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003170?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513003173?idApp=UINPBA000064"
      "url" => "/02116995/0000003300000003/v0_201502091323/X0211699513003173/v0_201502091323/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251413003162"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2012.Oct.11540"
    "estado" => "S300"
    "fechaPublicacion" => "2013-05-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2013;33:381-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6944
      "formatos" => array:3 [
        "EPUB" => 314
        "HTML" => 5959
        "PDF" => 671
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "The usefulness of intracellular adenosine-5'-triphosphate measurement in CD4+ cells in renal transplant"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "381"
          "paginaFinal" => "388"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Utilidad de la medición de adenosina 5'-trifosfato intracelular en células CD4+ en trasplante renal"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11540_16025_43324_en_t111540i.jpg"
              "Alto" => 444
              "Ancho" => 2161
              "Tamanyo" => 188832
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Summary of the number of rejections and infections per transplanted organ and their relationship with detected ATP"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Marcos López Hoyos, Marcos López-Hoyos, Emilio Rodrigo, Manuel Arias"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Marcos"
              "apellidos" => "López Hoyos"
            ]
            1 => array:2 [
              "nombre" => "Marcos"
              "apellidos" => "López-Hoyos"
            ]
            2 => array:2 [
              "nombre" => "Emilio"
              "apellidos" => "Rodrigo"
            ]
            3 => array:2 [
              "nombre" => "Manuel"
              "apellidos" => "Arias"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699513003165"
        "doi" => "10.3265/Nefrologia.pre2012.Oct.11540"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513003165?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003162?idApp=UINPBA000064"
    "url" => "/20132514/0000003300000003/v0_201502091549/X2013251413003162/v0_201502091549/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251413003189"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2012.Nov.11648"
    "estado" => "S300"
    "fechaPublicacion" => "2013-05-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2013;33:372-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5438
      "formatos" => array:3 [
        "EPUB" => 323
        "HTML" => 4386
        "PDF" => 729
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Dehydration upon admission is a risk factor for incomplete recovery of renal function in children with haemolytic uremic syndrome"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "372"
          "paginaFinal" => "376"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "La deshidratación al ingreso es un factor de riesgo para la recuperación incompleta de la función renal en niños con síndrome urémico hemolítico"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11648_16025_44951_en_t111648i.jpg"
              "Alto" => 557
              "Ancho" => 2170
              "Tamanyo" => 232318
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Baseline demographic and anthropometric characteristics of the study sample"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "José María Ojeda, José M. Ojeda, Isolda Kohout, Eduardo Cuestas"
          "autores" => array:5 [
            0 => null
            1 => array:2 [
              "nombre" => "José María"
              "apellidos" => "Ojeda"
            ]
            2 => array:2 [
              "nombre" => "José M."
              "apellidos" => "Ojeda"
            ]
            3 => array:2 [
              "nombre" => "Isolda"
              "apellidos" => "Kohout"
            ]
            4 => array:2 [
              "nombre" => "Eduardo"
              "apellidos" => "Cuestas"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699513003181"
        "doi" => "10.3265/Nefrologia.pre2012.Nov.11648"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513003181?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003189?idApp=UINPBA000064"
    "url" => "/20132514/0000003300000003/v0_201502091549/X2013251413003189/v0_201502091549/en/main.assets"
  ]
  "en" => array:14 [
    "idiomaDefecto" => true
    "titulo" => "Turbid acellular peritoneal fluid and the use of calcium antagonists in peritoneal dialysis"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "377"
        "paginaFinal" => "380"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Loreley BETANCOURT CASTELLANOS, Loreley Betancourt-Castellanos, Esther Ponz Clemente, Esther Ponz-Clemente, Maria Sol Otero López, M. Sol Otero-López, Conchita Blasco Cabañas, Conchita Blasco-Cabañas, Dolors Marquina Parra, Dolors Marquina-Parra, Manuel GARCIA GARCIA, Manuel García-García"
        "autores" => array:12 [
          0 => array:4 [
            "nombre" => "Loreley"
            "apellidos" => "BETANCOURT CASTELLANOS"
            "email" => array:1 [
              0 => "lorelaybc@hotmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:4 [
            "nombre" => "Loreley"
            "apellidos" => "Betancourt-Castellanos"
            "email" => array:1 [
              0 => "lorelaybc&#64;hotmail&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Esther"
            "apellidos" => "Ponz Clemente"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Esther"
            "apellidos" => "Ponz-Clemente"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Maria Sol"
            "apellidos" => "Otero L&#243;pez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "M&#46; Sol"
            "apellidos" => "Otero-L&#243;pez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Conchita"
            "apellidos" => "Blasco Caba&#241;as"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Conchita"
            "apellidos" => "Blasco-Caba&#241;as"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Dolors"
            "apellidos" => "Marquina Parra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Dolors"
            "apellidos" => "Marquina-Parra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "Manuel"
            "apellidos" => "GARCIA GARCIA"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "Manuel"
            "apellidos" => "Garc&#237;a-Garc&#237;a"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => "Unidad de Nefrología, Corporació Sanitària i Universitària Parc Taulí. UAB. Sabadell, SABADELL, Barcelona, Spain, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Unidad de Nefrología, Corporació Sanitària i Universitària Parc Taulí. UAB, Sabadell, Barcelona,  "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Unidad de Nefrología, Corporació Sanitària i Universitària Parc Taulí. UAB. Sabadell, Sabadell, Barcelona, Spain, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "L&#237;quido peritoneal turbio acelular y uso de antagonistas del calcio en di&#225;lisis peritoneal"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11697_19157_46467_en_t1_11697.jpg"
            "Alto" => 373
            "Ancho" => 2180
            "Tamanyo" => 164569
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Summary of the four cases of turbid acellular peritoneal fluid"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara">Turbid acellular peritoneal fluid &#40;TAPF&#41; of non-infectious aetiology is an uncommon entity in peritoneal dialysis &#40;PD&#41;&#46; This condition is characterised by cloudy peritoneal fluid with a high content of lymphatic fluid and triglycerides &#40;TG&#41;&#44; without the presence of leukocytes&#46; The most frequent causes are cancers such as lymphomas&#44; cirrhosis&#44; lymphatic obstructions&#44; pancreatitis&#44; trauma&#44; nephrotic syndrome&#44; and even the use of certain medications&#46;<span class="elsevierStyleSup">1-3</span> The most commonly reported drugs in association with this condition are dihydropyridine calcium antagonists &#40;CA&#41;&#44; such as lecarnidipine&#44;<span class="elsevierStyleSup">4&#44;5</span> manidipine&#44; and nifedipine&#46;<span class="elsevierStyleSup">6&#44;7</span> The largest studies thus far carried out in relation to this entity have dealt with patients of Asian descent&#44;<span class="elsevierStyleSup">4&#44;6&#44;7</span> and all reported significant TG levels increases in TAPF&#46;<span class="elsevierStyleSup">4&#44;6&#44;7</span></p><p class="elsevierStylePara">During the 2008-2010 period&#44; we diagnosed 4 cases of TAPF related to the use of CA at our institution&#46; Based on these cases&#44; we established the following objectives&#58; to review cases of TAPF&#44; their main characteristics&#44; and their relationship with the use of CA&#44; and to examine the relationship between treatment with CA and TG levels in peritoneal fluid &#40;PF&#41; in prevalent patients on PD&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">MATERIAL AND METHOD</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">In 2010&#44; TG levels were measured in 24-hour peritoneal effluent for all clinically stable prevalent patients on PD&#46; We reviewed anti-hypertensive treatment prescriptions and the use of CA in these patients&#46; We also closely reviewed the four cases of TAPF diagnosis at our institution&#44; the complementary tests carried out&#44; and patient evolution&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">CLINICAL CASES AND RESULTS</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Case 1&#58;</span> 60-year-old male with chronic kidney disease &#40;CKD&#41; secondary to nephroangiosclerosis&#44; who developed TAPF two months after commencing PD&#46; Laboratory analyses revealed normal values for amylase levels and liver parameters&#46; Microbiological cultures of PF for bacteria&#44; fungal contamination&#44; and mycobacteria were all negative&#46; Malignant cell cytology tests were also negative&#46; An abdominal computed axial tomography was normal&#46; Manidipine was finally suspended&#44; resulting in immediate alleviation of the symptoms&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Case 2&#58;</span> 41-year-old male with CKD secondary to diabetic nephropathy who developed TAPF four months after starting PD&#46; The patient was on treatment with verapamil&#46; Complementary tests and peritoneal fluid cultures were all negative&#46; TG levels as measured in this patient were 9mg&#47;dl&#44; but the PF returned to normal as soon as medication was suspended&#46; We believe that the cause of the cloudy fluid was treatment with CA&#44; although we could not demonstrate high TG levels&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Case 3&#58;</span> 70-year-old female with CKD of an unknown aetiology who developed TAPF four days after the laparoscopic placement of a PD catheter &#40;Figure 1&#41;&#46; The initial suspicion was one of a lymphatic trauma following catheter placement&#44; but removal of manidipine from the treatment regimen resolved the issue&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Case 4&#58;</span> 52-year-old male with chronic renal failure secondary to nephroangiosclerosis who developed a genital leak and TAPF 5 months after starting PD&#46; The patient was on treatment with manidipine&#44; and the PF returned to normal upon suspension of the medication&#46;</p><p class="elsevierStylePara">It is interesting to note that all patients were on treatment with CA as part of their regular prescription prior to the start of PD&#46;</p><p class="elsevierStylePara">The main characteristics of each patient and TG levels are summarised in Table 1&#46;</p><p class="elsevierStylePara">In 2010&#44; a total of 42 patients received PD&#44; 69&#37; of which were male&#44; with a mean age of 66 years&#46; In addition&#44; 69&#37; were on manual peritoneal dialysis techniques and 45&#37; were on treatment with some type of CA &#40;50&#37; nifedipine&#44; 31&#37; amlodipine&#44; 13&#37; manidipine&#44; and 6&#37; diltiazem&#41;&#46; We obtained 24-hour PF TG levels in 36 patients&#46; Mean TG levels were 8&#46;1mg&#47;dl&#44; with a range of 1-35mg&#47;dl&#44; and mean TG levels were very similar between patients with and without treatment with CA&#44; at 7&#46;81mg&#47;dl and 8&#46;6mg&#47;dl&#44; respectively&#46; We did not observe significant differences in TG values based on the type of CA administered&#44; although manidipine produced the highest levels &#40;Table 2&#41;&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">We present a four-case series of TAPF associated with treatment with CA&#44; the largest such study reported in Europe&#46; The closest such study from the continent came from Turkey&#44; in which three patients treated with lecarnidipine were analysed&#46;<span class="elsevierStyleSup">5</span> Recently&#44; an isolated case was reported in Spain in association with the administration of manidipine&#46;<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">We also describe the first case of TAPF associated with verapamil&#59; although a recent publication reported a case associated with a non-dihydropyridine CA&#44; diltiazem&#46;<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara">We also observed a high incidence of cases related to the use of manidipine&#46; In our study&#44; 75&#37; of patients with TAPF were on treatment with this drug&#46; These results are in accordance with those from the study by Yoshimoto et al&#46; in 1998&#44; in which 15 Japanese hospitals participated&#44; with a total of 251 patients on PD&#46; These authors describe 19 patients with TAPF associated with treatment with CA&#44; of which 78&#37; were on treatment with manidipine&#46; A total of 42&#37; of all patients on PD who received this drug developed TAPF&#46;<span class="elsevierStyleSup">7</span></p><p class="elsevierStylePara">Cases have also been published in Taiwan and Turkey of patients on treatment with lecarnidipine&#44; in which 58&#37; of individuals receiving this medication developed TAPF&#46;<span class="elsevierStyleSup">4&#44;5</span> during this period&#44; we did not observe any patients on treatment with lecarnidipine&#46; Isolated cases of TAPF have also been reported in association with treatment with benidipine&#44; nisoldipine&#44; and nifedipine&#46;<span class="elsevierStyleSup">7</span> In our experience&#44; we have not observed any cases of TAPF in association with nifedipine&#44; despite prescribing this treatment in 50&#37; of patients&#46;</p><p class="elsevierStylePara">As regards the TAPF diagnosis&#44; it is important to carry out a differential diagnosis in order to rule out other potentially severe causes&#46; With 20 years of experience at our PD unit&#44; we have never recorded a case of TAPF associated with cancer or pancreatitis&#46; The primary indicator of a possible case of TAPF associated with CA treatment is an increase in TG concentrations in PF&#46; The mean TG in the PF from the lecarnidipine study was 128&#46;4mg&#47;dl&#46;<span class="elsevierStyleSup">4</span> In a recently published case of TAPF associated with manidipine&#44; mean TG was 314mg&#47;dl&#44; higher than the standard values reported in the medical literature&#46;</p><p class="elsevierStylePara">In our analysis of TG concentrations in normal PF in our patients&#44; we obtained a mean value of 8&#46;1mg&#47;dl&#44; with a range of 1-35mg&#47;dl&#44; lower than the mean levels reported for TG in TAPF&#44; which tend to surpass 100mg&#47;dl&#46;<span class="elsevierStyleSup">4&#44;8</span> We also observed similar TG values in patients on treatment with CA and those not on CA&#46; As such&#44; the use of CA in patients with normal PF does not produce high TG levels in PF&#46;</p><p class="elsevierStylePara">In an effort to describe the possible causes of this phenomenon&#44; several authors have mentioned the action of CA on the peritoneal membrane&#44; resulting in increased perfusion and peritoneal function&#44;<span class="elsevierStyleSup">10&#44;11</span> which is attributed to the reduction produced by CA in inflammatory cytokines&#46;<span class="elsevierStyleSup">12&#44;13</span> Third-generation CA&#44; such as manidipine&#44; lercadipine&#44; amlodipine&#44; nivaldipine&#44; and efonidipine&#44; are capable of blocking both type L and type T calcium channels&#44; the latter being active only during cell proliferation&#46; These are very lipophilic molecules&#44;<span class="elsevierStyleSup">13&#44;14</span> which may act in the smooth muscle cells of the lymph vessels within the digestive tract&#44; thus hindering lymph return&#46; The geographic distribution of several studies carried out in Asia and very few in the rest of the world might suggest a genetic factor and ethnic predisposition&#44;<span class="elsevierStyleSup">4&#44;6&#44;7</span> although the causes have yet to be elucidated&#46; All of our patients were Caucasian&#46;</p><p class="elsevierStylePara">To conclude&#44; we believe that CA should be considered as a cause of non-infectious TAPF in patients on PD&#46; In our experience&#44; the CA that most frequently produced TAPF was manidipine&#44; and lecarnidipine should also be used with caution based on the results described in Asian studies&#46; Taking into account our results&#44; we do not believe that it is necessary to measure TG in the PF of patients on treatment with CA&#44; since there were no differences observed between patients based on treatment with or without CA&#44; or based on type of CA used&#46; The removal or limitation of these drugs in patients on PD is not justified solely based on this phenomenon&#46; If an episode of TAPF occurs&#44; removing the implicated drug or switching to a less lipophilic CA should be considered&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The authors declare that they have no conflicts of interest related to the content of this article&#46;</p><p class="elsevierStylePara"><a href="grande&#47;11697&#95;19157&#95;46467&#95;en&#95;t1&#95;11697&#46;jpg" class="elsevierStyleCrossRefs"><img src="11697_19157_46467_en_t1_11697.jpg" alt="Summary of the four cases of turbid acellular peritoneal fluid"></img></a></p><p class="elsevierStylePara">Table 1&#46; Summary of the four cases of turbid acellular peritoneal fluid</p><p class="elsevierStylePara"><a href="grande&#47;11697&#95;19157&#95;46468&#95;en&#95;t2116973&#46;jpg" class="elsevierStyleCrossRefs"><img src="11697_19157_46468_en_t2116973.jpg" alt="Mean triglyceride levels according to type of calcium antagonist administered"></img></a></p><p class="elsevierStylePara">Table 2&#46; Mean triglyceride levels according to type of calcium antagonist administered</p><p class="elsevierStylePara"><a href="grande&#47;11697&#95;19157&#95;46469&#95;en&#95;f1116972&#46;jpg" class="elsevierStyleCrossRefs"><img src="11697_19157_46469_en_f1116972.jpg" alt="Turbid acellular peritoneal fluid from a patient treated with manidipine"></img></a></p><p class="elsevierStylePara">Figure 1&#46; Turbid acellular peritoneal fluid from a patient treated with manidipine</p>"
    "pdfFichero" => "P1-E550-S4066-A11697-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:2 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec436075"
          "palabras" => array:1 [
            0 => "L&#237;quido peritoneal turbio"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec436077"
          "palabras" => array:1 [
            0 => "Antagonistas del calcio"
          ]
        ]
      ]
      "en" => array:2 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec436076"
          "palabras" => array:1 [
            0 => "Calcium antagonists"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec436078"
          "palabras" => array:1 [
            0 => "Cloudy peritoneal fluid"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">El l&#237;quido peritoneal turbio acelular de etiolog&#237;a no infecciosa es una entidad poco frecuente en di&#225;lisis peritoneal y se caracteriza por una concentraci&#243;n elevada de triglic&#233;ridos en el l&#237;quido peritoneal&#46; Las causas m&#225;s comunes son las neoplasias&#44;&#160;las obstrucciones linf&#225;ticas&#44; las pancreatitis&#44; los traumatismos y se ha relacionado tambi&#233;n con el uso de algunos f&#225;rmacos&#44; como los antagonistas del calcio&#46; Las series con un mayor n&#250;mero de casos se han comunicado en poblaci&#243;n asi&#225;tica&#46; Recientemente hemos diagnosticado en nuestro centro 4 casos de l&#237;quido peritoneal turbio acelular relacionado con el uso de antagonistas del calcio&#46; Nos planteamos revisar las caracter&#237;sticas principales de los casos y estudiar la relaci&#243;n del antagonista del calcio con los niveles de triglic&#233;ridos en el l&#237;quido peritoneal de los pacientes estables en di&#225;lisis peritoneal durante el a&#241;o 2010&#46; De los cuatro enfermos con l&#237;quido peritoneal turbio acelular&#44; el 75 &#37; eran varones y el 75 &#37; estaban en tratamiento con manidipino&#59; en todos los casos se resolvi&#243; el problema con la retirada del f&#225;rmaco&#46; Los niveles de triglic&#233;ridos medios fueron de 314 mg&#47;dl&#46; Los niveles medios de triglic&#233;ridos de 36 pacientes estables de di&#225;lisis peritoneal fueron de 8&#44;1 mg&#47;dl&#44; con un intervalo entre 1 y 35 mg&#47;dl&#46; La media de triglic&#233;ridos en los pacientes con o sin tratamiento con antagonistas del calcio fue muy similar&#58; 7&#44;81 y 8&#44;6 mg&#47;dl&#44; respectivamente&#46; No se observaron diferencias en relaci&#243;n con el tipo de antagonista del calcio prescrito&#46; En nuestra experiencia&#44; creemos que los antagonistas del calcio deben ser considerados como causa de l&#237;quido peritoneal turbio acelular en los enfermos en di&#225;lisis peritoneal&#44; en especial el manidipino&#46; No consideramos &#250;til la determinaci&#243;n de triglic&#233;ridos en el l&#237;quido peritoneal de los enfermos asintom&#225;ticos en tratamiento con antagonistas del calcio&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">&#160;</p> <p class="elsevierStylePara">Turbid acellular peritoneal fluid of a non-infectious aetiology is an uncommon entity in peritoneal dialysis and is characterised by a high concentration of triglycerides in the peritoneal fluid&#46; The most common causes include cancer&#44; lymphatic obstructions&#44; pancreatitis&#44; trauma&#44; and even the use of certain medications such as calcium antagonists&#46; The largest studies concerning this entity have been carried out in patients of Asian descent&#46; We recently diagnosed 4 cases of turbid acellular peritoneal fluid at our institution in relation to the use of calcium antagonists&#46; We reviewed the primary characteristics of these cases and examined the relationship between the use of calcium antagonists and triglyceride levels in the peritoneal fluid of stable patients on peritoneal dialysis during 2010&#46;</p> <p class="elsevierStylePara">Of the four patients with turbid acellular peritoneal fluid&#44; 75&#37; were male and 75&#37; were on treatment with manidipine&#59; in all cases&#44; the issue was resolved by suspending medication&#46; Mean triglyceride levels were 314mg&#47;dl&#46; Mean triglyceride levels in 36 stable patients on peritoneal dialysis were 8&#46;1mg&#47;dl&#44; with a range of 1-35mg&#47;dl&#46; Mean triglyceride levels in patients with and without calcium antagonist treatment were very similar&#44; at 7&#46;81mg&#47;dl and 8&#46;6mg&#47;dl&#44; respectively&#46; We did not observe significant differences in terms of the type of calcium antagonist prescribed&#46;</p> <p class="elsevierStylePara">In our experience&#44; we believe that calcium antagonists should be considered as a cause of turbid acellular peritoneal fluid in patients on peritoneal dialysis&#44; in particular manidipine&#46; We do not find it useful to determine triglyceride levels in the peritoneal fluid of asymptomatic patients on treatment with calcium antagonists&#46;<span class="elsevierStyleItalic">&#160;</span></p>"
      ]
    ]
    "multimedia" => array:3 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11697_19157_46467_en_t1_11697.jpg"
            "Alto" => 373
            "Ancho" => 2180
            "Tamanyo" => 164569
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Summary of the four cases of turbid acellular peritoneal fluid"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11697_19157_46468_en_t2116973.jpg"
            "Alto" => 205
            "Ancho" => 2169
            "Tamanyo" => 98011
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Mean triglyceride levels according to type of calcium antagonist administered"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11697_19157_46469_en_f1116972.jpg"
            "Alto" => 645
            "Ancho" => 1017
            "Tamanyo" => 108214
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Turbid acellular peritoneal fluid from a patient treated with manidipine"
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003300000003/v0_201502091549/X2013251413003170/v0_201502091549/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35444"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Short Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003300000003/v0_201502091549/X2013251413003170/v0_201502091549/en/P1-E550-S4066-A11697-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003170?idApp=UINPBA000064"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Turbid acellular peritoneal fluid and the use of calcium antagonists in peritoneal dialysis
Líquido peritoneal turbio acelular y uso de antagonistas del calcio en diálisis peritoneal
Loreley BETANCOURT CASTELLANOSa, Loreley Betancourt-Castellanosb, Esther Ponz Clementec, Esther Ponz-Clementeb, Maria Sol Otero Lópezc, M. Sol Otero-Lópezb, Conchita Blasco Cabañasc, Conchita Blasco-Cabañasb, Dolors Marquina Parrac, Dolors Marquina-Parrab, Manuel GARCIA GARCIAc, Manuel García-Garcíab
a Unidad de Nefrología, Corporació Sanitària i Universitària Parc Taulí. UAB. Sabadell, SABADELL, Barcelona, Spain,
b Unidad de Nefrología, Corporació Sanitària i Universitària Parc Taulí. UAB, Sabadell, Barcelona,
c Unidad de Nefrología, Corporació Sanitària i Universitària Parc Taulí. UAB. Sabadell, Sabadell, Barcelona, Spain,
Read
10708
Times
was read the article
2647
Total PDF
8061
Total HTML
Share statistics
 array:21 [
  "pii" => "X2013251413003170"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2013.Feb.11697"
  "estado" => "S300"
  "fechaPublicacion" => "2013-05-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia &#40;English Version&#41;. 2013;33:377-80"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 6037
    "formatos" => array:3 [
      "EPUB" => 304
      "HTML" => 5062
      "PDF" => 671
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699513003173"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2013.Feb.11697"
      "estado" => "S300"
      "fechaPublicacion" => "2013-05-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2013;33:377-80"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 14148
        "formatos" => array:3 [
          "EPUB" => 295
          "HTML" => 13233
          "PDF" => 620
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "L&#237;quido peritoneal turbio acelular y uso de antagonistas del calcio en di&#225;lisis peritoneal"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "377"
            "paginaFinal" => "380"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Turbid acellular peritoneal fluid and the use of calcium antagonists in peritoneal dialysis"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig1"
            "etiqueta" => "Fig. 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier Espa&#241;a"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "11697_19904_35171_es_11697_f1.jpg"
                "Alto" => 579
                "Ancho" => 900
                "Tamanyo" => 144348
              ]
            ]
            "descripcion" => array:1 [
              "es" => "L&#237;quido peritoneal turbio acelular en paciente tratado con manidipino"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Loreley BETANCOURT CASTELLANOS, Loreley Betancourt-Castellanos, Esther Ponz Clemente, Esther Ponz-Clemente, Maria Sol Otero L&#243;pez, M&#46; Sol Otero-L&#243;pez, Conchita Blasco Caba&#241;as, Conchita Blasco-Caba&#241;as, Dolors Marquina Parra, Dolors Marquina-Parra, Manuel GARCIA GARCIA, Manuel Garc&#237;a-Garc&#237;a"
            "autores" => array:12 [
              0 => array:2 [
                "nombre" => "Loreley"
                "apellidos" => "BETANCOURT CASTELLANOS"
              ]
              1 => array:2 [
                "nombre" => "Loreley"
                "apellidos" => "Betancourt-Castellanos"
              ]
              2 => array:2 [
                "nombre" => "Esther"
                "apellidos" => "Ponz Clemente"
              ]
              3 => array:2 [
                "nombre" => "Esther"
                "apellidos" => "Ponz-Clemente"
              ]
              4 => array:2 [
                "nombre" => "Maria Sol"
                "apellidos" => "Otero L&#243;pez"
              ]
              5 => array:2 [
                "nombre" => "M&#46; Sol"
                "apellidos" => "Otero-L&#243;pez"
              ]
              6 => array:2 [
                "nombre" => "Conchita"
                "apellidos" => "Blasco Caba&#241;as"
              ]
              7 => array:2 [
                "nombre" => "Conchita"
                "apellidos" => "Blasco-Caba&#241;as"
              ]
              8 => array:2 [
                "nombre" => "Dolors"
                "apellidos" => "Marquina Parra"
              ]
              9 => array:2 [
                "nombre" => "Dolors"
                "apellidos" => "Marquina-Parra"
              ]
              10 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "GARCIA GARCIA"
              ]
              11 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "Garc&#237;a-Garc&#237;a"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251413003170"
          "doi" => "10.3265/Nefrologia.pre2013.Feb.11697"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003170?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513003173?idApp=UINPBA000064"
      "url" => "/02116995/0000003300000003/v0_201502091323/X0211699513003173/v0_201502091323/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251413003162"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2012.Oct.11540"
    "estado" => "S300"
    "fechaPublicacion" => "2013-05-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2013;33:381-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6944
      "formatos" => array:3 [
        "EPUB" => 314
        "HTML" => 5959
        "PDF" => 671
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "The usefulness of intracellular adenosine-5&#39;-triphosphate measurement in CD4&#43; cells in renal transplant"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "381"
          "paginaFinal" => "388"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Utilidad de la medici&#243;n de adenosina 5&#39;-trifosfato intracelular en c&#233;lulas CD4&#43; en trasplante renal"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11540_16025_43324_en_t111540i.jpg"
              "Alto" => 444
              "Ancho" => 2161
              "Tamanyo" => 188832
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Summary of the number of rejections and infections per transplanted organ and their relationship with detected ATP"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Marcos L&#243;pez Hoyos, Marcos L&#243;pez-Hoyos, Emilio Rodrigo, Manuel Arias"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Marcos"
              "apellidos" => "L&#243;pez Hoyos"
            ]
            1 => array:2 [
              "nombre" => "Marcos"
              "apellidos" => "L&#243;pez-Hoyos"
            ]
            2 => array:2 [
              "nombre" => "Emilio"
              "apellidos" => "Rodrigo"
            ]
            3 => array:2 [
              "nombre" => "Manuel"
              "apellidos" => "Arias"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699513003165"
        "doi" => "10.3265/Nefrologia.pre2012.Oct.11540"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513003165?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003162?idApp=UINPBA000064"
    "url" => "/20132514/0000003300000003/v0_201502091549/X2013251413003162/v0_201502091549/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251413003189"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2012.Nov.11648"
    "estado" => "S300"
    "fechaPublicacion" => "2013-05-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2013;33:372-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5438
      "formatos" => array:3 [
        "EPUB" => 323
        "HTML" => 4386
        "PDF" => 729
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Dehydration upon admission is a risk factor for incomplete recovery of renal function in children with haemolytic uremic syndrome"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "372"
          "paginaFinal" => "376"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "La deshidrataci&#243;n al ingreso es un factor de riesgo para la recuperaci&#243;n incompleta de la funci&#243;n renal en ni&#241;os con s&#237;ndrome ur&#233;mico hemol&#237;tico"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11648_16025_44951_en_t111648i.jpg"
              "Alto" => 557
              "Ancho" => 2170
              "Tamanyo" => 232318
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Baseline demographic and anthropometric characteristics of the study sample"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Jos&#233; Mar&#237;a Ojeda, Jos&#233; M&#46; Ojeda, Isolda Kohout, Eduardo Cuestas"
          "autores" => array:5 [
            0 => null
            1 => array:2 [
              "nombre" => "Jos&#233; Mar&#237;a"
              "apellidos" => "Ojeda"
            ]
            2 => array:2 [
              "nombre" => "Jos&#233; M&#46;"
              "apellidos" => "Ojeda"
            ]
            3 => array:2 [
              "nombre" => "Isolda"
              "apellidos" => "Kohout"
            ]
            4 => array:2 [
              "nombre" => "Eduardo"
              "apellidos" => "Cuestas"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699513003181"
        "doi" => "10.3265/Nefrologia.pre2012.Nov.11648"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513003181?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003189?idApp=UINPBA000064"
    "url" => "/20132514/0000003300000003/v0_201502091549/X2013251413003189/v0_201502091549/en/main.assets"
  ]
  "en" => array:14 [
    "idiomaDefecto" => true
    "titulo" => "Turbid acellular peritoneal fluid and the use of calcium antagonists in peritoneal dialysis"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "377"
        "paginaFinal" => "380"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Loreley BETANCOURT CASTELLANOS, Loreley Betancourt-Castellanos, Esther Ponz Clemente, Esther Ponz-Clemente, Maria Sol Otero L&#243;pez, M&#46; Sol Otero-L&#243;pez, Conchita Blasco Caba&#241;as, Conchita Blasco-Caba&#241;as, Dolors Marquina Parra, Dolors Marquina-Parra, Manuel GARCIA GARCIA, Manuel Garc&#237;a-Garc&#237;a"
        "autores" => array:12 [
          0 => array:4 [
            "nombre" => "Loreley"
            "apellidos" => "BETANCOURT CASTELLANOS"
            "email" => array:1 [
              0 => "lorelaybc&#64;hotmail&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:4 [
            "nombre" => "Loreley"
            "apellidos" => "Betancourt-Castellanos"
            "email" => array:1 [
              0 => "lorelaybc&#64;hotmail&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Esther"
            "apellidos" => "Ponz Clemente"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Esther"
            "apellidos" => "Ponz-Clemente"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Maria Sol"
            "apellidos" => "Otero L&#243;pez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "M&#46; Sol"
            "apellidos" => "Otero-L&#243;pez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Conchita"
            "apellidos" => "Blasco Caba&#241;as"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Conchita"
            "apellidos" => "Blasco-Caba&#241;as"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Dolors"
            "apellidos" => "Marquina Parra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Dolors"
            "apellidos" => "Marquina-Parra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "Manuel"
            "apellidos" => "GARCIA GARCIA"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "Manuel"
            "apellidos" => "Garc&#237;a-Garc&#237;a"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => "Unidad de Nefrología, Corporació Sanitària i Universitària Parc Taulí. UAB. Sabadell, SABADELL, Barcelona, Spain, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Unidad de Nefrología, Corporació Sanitària i Universitària Parc Taulí. UAB, Sabadell, Barcelona,  "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Unidad de Nefrología, Corporació Sanitària i Universitària Parc Taulí. UAB. Sabadell, Sabadell, Barcelona, Spain, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "L&#237;quido peritoneal turbio acelular y uso de antagonistas del calcio en di&#225;lisis peritoneal"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11697_19157_46467_en_t1_11697.jpg"
            "Alto" => 373
            "Ancho" => 2180
            "Tamanyo" => 164569
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Summary of the four cases of turbid acellular peritoneal fluid"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara">Turbid acellular peritoneal fluid &#40;TAPF&#41; of non-infectious aetiology is an uncommon entity in peritoneal dialysis &#40;PD&#41;&#46; This condition is characterised by cloudy peritoneal fluid with a high content of lymphatic fluid and triglycerides &#40;TG&#41;&#44; without the presence of leukocytes&#46; The most frequent causes are cancers such as lymphomas&#44; cirrhosis&#44; lymphatic obstructions&#44; pancreatitis&#44; trauma&#44; nephrotic syndrome&#44; and even the use of certain medications&#46;<span class="elsevierStyleSup">1-3</span> The most commonly reported drugs in association with this condition are dihydropyridine calcium antagonists &#40;CA&#41;&#44; such as lecarnidipine&#44;<span class="elsevierStyleSup">4&#44;5</span> manidipine&#44; and nifedipine&#46;<span class="elsevierStyleSup">6&#44;7</span> The largest studies thus far carried out in relation to this entity have dealt with patients of Asian descent&#44;<span class="elsevierStyleSup">4&#44;6&#44;7</span> and all reported significant TG levels increases in TAPF&#46;<span class="elsevierStyleSup">4&#44;6&#44;7</span></p><p class="elsevierStylePara">During the 2008-2010 period&#44; we diagnosed 4 cases of TAPF related to the use of CA at our institution&#46; Based on these cases&#44; we established the following objectives&#58; to review cases of TAPF&#44; their main characteristics&#44; and their relationship with the use of CA&#44; and to examine the relationship between treatment with CA and TG levels in peritoneal fluid &#40;PF&#41; in prevalent patients on PD&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">MATERIAL AND METHOD</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">In 2010&#44; TG levels were measured in 24-hour peritoneal effluent for all clinically stable prevalent patients on PD&#46; We reviewed anti-hypertensive treatment prescriptions and the use of CA in these patients&#46; We also closely reviewed the four cases of TAPF diagnosis at our institution&#44; the complementary tests carried out&#44; and patient evolution&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">CLINICAL CASES AND RESULTS</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Case 1&#58;</span> 60-year-old male with chronic kidney disease &#40;CKD&#41; secondary to nephroangiosclerosis&#44; who developed TAPF two months after commencing PD&#46; Laboratory analyses revealed normal values for amylase levels and liver parameters&#46; Microbiological cultures of PF for bacteria&#44; fungal contamination&#44; and mycobacteria were all negative&#46; Malignant cell cytology tests were also negative&#46; An abdominal computed axial tomography was normal&#46; Manidipine was finally suspended&#44; resulting in immediate alleviation of the symptoms&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Case 2&#58;</span> 41-year-old male with CKD secondary to diabetic nephropathy who developed TAPF four months after starting PD&#46; The patient was on treatment with verapamil&#46; Complementary tests and peritoneal fluid cultures were all negative&#46; TG levels as measured in this patient were 9mg&#47;dl&#44; but the PF returned to normal as soon as medication was suspended&#46; We believe that the cause of the cloudy fluid was treatment with CA&#44; although we could not demonstrate high TG levels&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Case 3&#58;</span> 70-year-old female with CKD of an unknown aetiology who developed TAPF four days after the laparoscopic placement of a PD catheter &#40;Figure 1&#41;&#46; The initial suspicion was one of a lymphatic trauma following catheter placement&#44; but removal of manidipine from the treatment regimen resolved the issue&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Case 4&#58;</span> 52-year-old male with chronic renal failure secondary to nephroangiosclerosis who developed a genital leak and TAPF 5 months after starting PD&#46; The patient was on treatment with manidipine&#44; and the PF returned to normal upon suspension of the medication&#46;</p><p class="elsevierStylePara">It is interesting to note that all patients were on treatment with CA as part of their regular prescription prior to the start of PD&#46;</p><p class="elsevierStylePara">The main characteristics of each patient and TG levels are summarised in Table 1&#46;</p><p class="elsevierStylePara">In 2010&#44; a total of 42 patients received PD&#44; 69&#37; of which were male&#44; with a mean age of 66 years&#46; In addition&#44; 69&#37; were on manual peritoneal dialysis techniques and 45&#37; were on treatment with some type of CA &#40;50&#37; nifedipine&#44; 31&#37; amlodipine&#44; 13&#37; manidipine&#44; and 6&#37; diltiazem&#41;&#46; We obtained 24-hour PF TG levels in 36 patients&#46; Mean TG levels were 8&#46;1mg&#47;dl&#44; with a range of 1-35mg&#47;dl&#44; and mean TG levels were very similar between patients with and without treatment with CA&#44; at 7&#46;81mg&#47;dl and 8&#46;6mg&#47;dl&#44; respectively&#46; We did not observe significant differences in TG values based on the type of CA administered&#44; although manidipine produced the highest levels &#40;Table 2&#41;&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">We present a four-case series of TAPF associated with treatment with CA&#44; the largest such study reported in Europe&#46; The closest such study from the continent came from Turkey&#44; in which three patients treated with lecarnidipine were analysed&#46;<span class="elsevierStyleSup">5</span> Recently&#44; an isolated case was reported in Spain in association with the administration of manidipine&#46;<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">We also describe the first case of TAPF associated with verapamil&#59; although a recent publication reported a case associated with a non-dihydropyridine CA&#44; diltiazem&#46;<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara">We also observed a high incidence of cases related to the use of manidipine&#46; In our study&#44; 75&#37; of patients with TAPF were on treatment with this drug&#46; These results are in accordance with those from the study by Yoshimoto et al&#46; in 1998&#44; in which 15 Japanese hospitals participated&#44; with a total of 251 patients on PD&#46; These authors describe 19 patients with TAPF associated with treatment with CA&#44; of which 78&#37; were on treatment with manidipine&#46; A total of 42&#37; of all patients on PD who received this drug developed TAPF&#46;<span class="elsevierStyleSup">7</span></p><p class="elsevierStylePara">Cases have also been published in Taiwan and Turkey of patients on treatment with lecarnidipine&#44; in which 58&#37; of individuals receiving this medication developed TAPF&#46;<span class="elsevierStyleSup">4&#44;5</span> during this period&#44; we did not observe any patients on treatment with lecarnidipine&#46; Isolated cases of TAPF have also been reported in association with treatment with benidipine&#44; nisoldipine&#44; and nifedipine&#46;<span class="elsevierStyleSup">7</span> In our experience&#44; we have not observed any cases of TAPF in association with nifedipine&#44; despite prescribing this treatment in 50&#37; of patients&#46;</p><p class="elsevierStylePara">As regards the TAPF diagnosis&#44; it is important to carry out a differential diagnosis in order to rule out other potentially severe causes&#46; With 20 years of experience at our PD unit&#44; we have never recorded a case of TAPF associated with cancer or pancreatitis&#46; The primary indicator of a possible case of TAPF associated with CA treatment is an increase in TG concentrations in PF&#46; The mean TG in the PF from the lecarnidipine study was 128&#46;4mg&#47;dl&#46;<span class="elsevierStyleSup">4</span> In a recently published case of TAPF associated with manidipine&#44; mean TG was 314mg&#47;dl&#44; higher than the standard values reported in the medical literature&#46;</p><p class="elsevierStylePara">In our analysis of TG concentrations in normal PF in our patients&#44; we obtained a mean value of 8&#46;1mg&#47;dl&#44; with a range of 1-35mg&#47;dl&#44; lower than the mean levels reported for TG in TAPF&#44; which tend to surpass 100mg&#47;dl&#46;<span class="elsevierStyleSup">4&#44;8</span> We also observed similar TG values in patients on treatment with CA and those not on CA&#46; As such&#44; the use of CA in patients with normal PF does not produce high TG levels in PF&#46;</p><p class="elsevierStylePara">In an effort to describe the possible causes of this phenomenon&#44; several authors have mentioned the action of CA on the peritoneal membrane&#44; resulting in increased perfusion and peritoneal function&#44;<span class="elsevierStyleSup">10&#44;11</span> which is attributed to the reduction produced by CA in inflammatory cytokines&#46;<span class="elsevierStyleSup">12&#44;13</span> Third-generation CA&#44; such as manidipine&#44; lercadipine&#44; amlodipine&#44; nivaldipine&#44; and efonidipine&#44; are capable of blocking both type L and type T calcium channels&#44; the latter being active only during cell proliferation&#46; These are very lipophilic molecules&#44;<span class="elsevierStyleSup">13&#44;14</span> which may act in the smooth muscle cells of the lymph vessels within the digestive tract&#44; thus hindering lymph return&#46; The geographic distribution of several studies carried out in Asia and very few in the rest of the world might suggest a genetic factor and ethnic predisposition&#44;<span class="elsevierStyleSup">4&#44;6&#44;7</span> although the causes have yet to be elucidated&#46; All of our patients were Caucasian&#46;</p><p class="elsevierStylePara">To conclude&#44; we believe that CA should be considered as a cause of non-infectious TAPF in patients on PD&#46; In our experience&#44; the CA that most frequently produced TAPF was manidipine&#44; and lecarnidipine should also be used with caution based on the results described in Asian studies&#46; Taking into account our results&#44; we do not believe that it is necessary to measure TG in the PF of patients on treatment with CA&#44; since there were no differences observed between patients based on treatment with or without CA&#44; or based on type of CA used&#46; The removal or limitation of these drugs in patients on PD is not justified solely based on this phenomenon&#46; If an episode of TAPF occurs&#44; removing the implicated drug or switching to a less lipophilic CA should be considered&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The authors declare that they have no conflicts of interest related to the content of this article&#46;</p><p class="elsevierStylePara"><a href="grande&#47;11697&#95;19157&#95;46467&#95;en&#95;t1&#95;11697&#46;jpg" class="elsevierStyleCrossRefs"><img src="11697_19157_46467_en_t1_11697.jpg" alt="Summary of the four cases of turbid acellular peritoneal fluid"></img></a></p><p class="elsevierStylePara">Table 1&#46; Summary of the four cases of turbid acellular peritoneal fluid</p><p class="elsevierStylePara"><a href="grande&#47;11697&#95;19157&#95;46468&#95;en&#95;t2116973&#46;jpg" class="elsevierStyleCrossRefs"><img src="11697_19157_46468_en_t2116973.jpg" alt="Mean triglyceride levels according to type of calcium antagonist administered"></img></a></p><p class="elsevierStylePara">Table 2&#46; Mean triglyceride levels according to type of calcium antagonist administered</p><p class="elsevierStylePara"><a href="grande&#47;11697&#95;19157&#95;46469&#95;en&#95;f1116972&#46;jpg" class="elsevierStyleCrossRefs"><img src="11697_19157_46469_en_f1116972.jpg" alt="Turbid acellular peritoneal fluid from a patient treated with manidipine"></img></a></p><p class="elsevierStylePara">Figure 1&#46; Turbid acellular peritoneal fluid from a patient treated with manidipine</p>"
    "pdfFichero" => "P1-E550-S4066-A11697-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:2 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec436075"
          "palabras" => array:1 [
            0 => "L&#237;quido peritoneal turbio"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec436077"
          "palabras" => array:1 [
            0 => "Antagonistas del calcio"
          ]
        ]
      ]
      "en" => array:2 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec436076"
          "palabras" => array:1 [
            0 => "Calcium antagonists"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec436078"
          "palabras" => array:1 [
            0 => "Cloudy peritoneal fluid"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">El l&#237;quido peritoneal turbio acelular de etiolog&#237;a no infecciosa es una entidad poco frecuente en di&#225;lisis peritoneal y se caracteriza por una concentraci&#243;n elevada de triglic&#233;ridos en el l&#237;quido peritoneal&#46; Las causas m&#225;s comunes son las neoplasias&#44;&#160;las obstrucciones linf&#225;ticas&#44; las pancreatitis&#44; los traumatismos y se ha relacionado tambi&#233;n con el uso de algunos f&#225;rmacos&#44; como los antagonistas del calcio&#46; Las series con un mayor n&#250;mero de casos se han comunicado en poblaci&#243;n asi&#225;tica&#46; Recientemente hemos diagnosticado en nuestro centro 4 casos de l&#237;quido peritoneal turbio acelular relacionado con el uso de antagonistas del calcio&#46; Nos planteamos revisar las caracter&#237;sticas principales de los casos y estudiar la relaci&#243;n del antagonista del calcio con los niveles de triglic&#233;ridos en el l&#237;quido peritoneal de los pacientes estables en di&#225;lisis peritoneal durante el a&#241;o 2010&#46; De los cuatro enfermos con l&#237;quido peritoneal turbio acelular&#44; el 75 &#37; eran varones y el 75 &#37; estaban en tratamiento con manidipino&#59; en todos los casos se resolvi&#243; el problema con la retirada del f&#225;rmaco&#46; Los niveles de triglic&#233;ridos medios fueron de 314 mg&#47;dl&#46; Los niveles medios de triglic&#233;ridos de 36 pacientes estables de di&#225;lisis peritoneal fueron de 8&#44;1 mg&#47;dl&#44; con un intervalo entre 1 y 35 mg&#47;dl&#46; La media de triglic&#233;ridos en los pacientes con o sin tratamiento con antagonistas del calcio fue muy similar&#58; 7&#44;81 y 8&#44;6 mg&#47;dl&#44; respectivamente&#46; No se observaron diferencias en relaci&#243;n con el tipo de antagonista del calcio prescrito&#46; En nuestra experiencia&#44; creemos que los antagonistas del calcio deben ser considerados como causa de l&#237;quido peritoneal turbio acelular en los enfermos en di&#225;lisis peritoneal&#44; en especial el manidipino&#46; No consideramos &#250;til la determinaci&#243;n de triglic&#233;ridos en el l&#237;quido peritoneal de los enfermos asintom&#225;ticos en tratamiento con antagonistas del calcio&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">&#160;</p> <p class="elsevierStylePara">Turbid acellular peritoneal fluid of a non-infectious aetiology is an uncommon entity in peritoneal dialysis and is characterised by a high concentration of triglycerides in the peritoneal fluid&#46; The most common causes include cancer&#44; lymphatic obstructions&#44; pancreatitis&#44; trauma&#44; and even the use of certain medications such as calcium antagonists&#46; The largest studies concerning this entity have been carried out in patients of Asian descent&#46; We recently diagnosed 4 cases of turbid acellular peritoneal fluid at our institution in relation to the use of calcium antagonists&#46; We reviewed the primary characteristics of these cases and examined the relationship between the use of calcium antagonists and triglyceride levels in the peritoneal fluid of stable patients on peritoneal dialysis during 2010&#46;</p> <p class="elsevierStylePara">Of the four patients with turbid acellular peritoneal fluid&#44; 75&#37; were male and 75&#37; were on treatment with manidipine&#59; in all cases&#44; the issue was resolved by suspending medication&#46; Mean triglyceride levels were 314mg&#47;dl&#46; Mean triglyceride levels in 36 stable patients on peritoneal dialysis were 8&#46;1mg&#47;dl&#44; with a range of 1-35mg&#47;dl&#46; Mean triglyceride levels in patients with and without calcium antagonist treatment were very similar&#44; at 7&#46;81mg&#47;dl and 8&#46;6mg&#47;dl&#44; respectively&#46; We did not observe significant differences in terms of the type of calcium antagonist prescribed&#46;</p> <p class="elsevierStylePara">In our experience&#44; we believe that calcium antagonists should be considered as a cause of turbid acellular peritoneal fluid in patients on peritoneal dialysis&#44; in particular manidipine&#46; We do not find it useful to determine triglyceride levels in the peritoneal fluid of asymptomatic patients on treatment with calcium antagonists&#46;<span class="elsevierStyleItalic">&#160;</span></p>"
      ]
    ]
    "multimedia" => array:3 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11697_19157_46467_en_t1_11697.jpg"
            "Alto" => 373
            "Ancho" => 2180
            "Tamanyo" => 164569
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Summary of the four cases of turbid acellular peritoneal fluid"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11697_19157_46468_en_t2116973.jpg"
            "Alto" => 205
            "Ancho" => 2169
            "Tamanyo" => 98011
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Mean triglyceride levels according to type of calcium antagonist administered"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11697_19157_46469_en_f1116972.jpg"
            "Alto" => 645
            "Ancho" => 1017
            "Tamanyo" => 108214
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Turbid acellular peritoneal fluid from a patient treated with manidipine"
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003300000003/v0_201502091549/X2013251413003170/v0_201502091549/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35444"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Short Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003300000003/v0_201502091549/X2013251413003170/v0_201502091549/en/P1-E550-S4066-A11697-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413003170?idApp=UINPBA000064"
]
Article information
ISSN: 20132514
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 9 8 17
2024 October 52 62 114
2024 September 69 47 116
2024 August 63 74 137
2024 July 43 43 86
2024 June 68 53 121
2024 May 73 42 115
2024 April 62 45 107
2024 March 57 32 89
2024 February 52 36 88
2024 January 45 30 75
2023 December 39 44 83
2023 November 50 39 89
2023 October 58 49 107
2023 September 39 38 77
2023 August 43 37 80
2023 July 74 48 122
2023 June 82 38 120
2023 May 64 37 101
2023 April 58 28 86
2023 March 55 21 76
2023 February 61 24 85
2023 January 45 25 70
2022 December 87 37 124
2022 November 43 42 85
2022 October 65 40 105
2022 September 64 33 97
2022 August 76 32 108
2022 July 69 51 120
2022 June 57 37 94
2022 May 60 40 100
2022 April 80 53 133
2022 March 65 52 117
2022 February 50 40 90
2022 January 41 38 79
2021 December 68 30 98
2021 November 61 34 95
2021 October 63 55 118
2021 September 55 43 98
2021 August 47 40 87
2021 July 56 46 102
2021 June 33 22 55
2021 May 41 34 75
2021 April 61 40 101
2021 March 55 49 104
2021 February 70 31 101
2021 January 40 10 50
2020 December 34 22 56
2020 November 49 19 68
2020 October 31 20 51
2020 September 25 9 34
2020 August 37 6 43
2020 July 38 11 49
2020 June 20 19 39
2020 May 28 11 39
2020 April 21 14 35
2020 March 29 13 42
2020 February 38 16 54
2020 January 39 23 62
2019 December 51 17 68
2019 November 46 18 64
2019 October 43 9 52
2019 September 61 18 79
2019 August 50 9 59
2019 July 38 22 60
2019 June 34 10 44
2019 May 48 15 63
2019 April 79 34 113
2019 March 33 13 46
2019 February 52 17 69
2019 January 48 12 60
2018 December 121 43 164
2018 November 147 19 166
2018 October 149 20 169
2018 September 98 17 115
2018 August 54 52 106
2018 July 67 17 84
2018 June 63 16 79
2018 May 51 17 68
2018 April 87 4 91
2018 March 61 12 73
2018 February 72 12 84
2018 January 62 5 67
2017 December 67 9 76
2017 November 76 17 93
2017 October 43 7 50
2017 September 64 13 77
2017 August 103 14 117
2017 July 60 16 76
2017 June 52 9 61
2017 May 101 17 118
2017 April 49 15 64
2017 March 49 14 63
2017 February 114 10 124
2017 January 42 10 52
2016 December 67 6 73
2016 November 75 12 87
2016 October 171 12 183
2016 September 242 5 247
2016 August 218 7 225
2016 July 277 14 291
2016 June 169 0 169
2016 May 154 0 154
2016 April 119 0 119
2016 March 115 0 115
2016 February 131 0 131
2016 January 121 0 121
2015 December 128 0 128
2015 November 117 0 117
2015 October 112 0 112
2015 September 75 0 75
2015 August 62 0 62
2015 July 89 0 89
2015 June 41 0 41
2015 May 78 0 78
2015 April 8 0 8
Show all

Follow this link to access the full text of the article

Idiomas
Nefrología (English Edition)
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?